Dr. Tom Colleti, DHSc, MPAS, PA-C, DFAAPA
Most healthcare providers (HCPs) are familiar with the common causes of heart failure. However, minimal understanding exists around transthyretin amyloid cardiomyopathy (ATTR-CM), which is a type of cardiac amyloidosis that causes diastolic heart failure or heart failure with preserved ejection fraction (HFpEF).
ATTR-CM has been considered uncommon but evolving evidence is proving otherwise. It is a progressive, fatal disease and those affected are faced with a grim prognosis if not appropriately treated. Disease progression ultimately leads to heart failure that is refractory to standard medical therapies. Worsening symptoms result in frequent office visits and hospital readmissions, which cause significant pain and suffering to families and financial hardship to healthcare systems. Therefore, prompt recognition, diagnosis, and appropriate treatment are critical to improving outcomes and enhancing patient survivability.
Providing education on the disease state, prevalence, associated signs and symptoms, and the diagnostic pathway will assist HCPs in earlier recognition and diagnosis of this terminal disease.
Church S. Transthyretin Amyloid Cardiomyopathy: A Clinical Review. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.